key: cord-0867431-a2sr8elt
authors: Aviani, Jenifer Kiem; Halim, Danny; Soeroto, Arto Yuwono; Achmad, Tri Hanggono; Djuwantono, Tono
title: Current views on the potentials of convalescent plasma therapy (CPT) as Coronavirus disease 2019 (COVID‐19) treatment: A systematic review and meta‐analysis based on recent studies and previous respiratory pandemics
date: 2021-02-23
journal: Rev Med Virol
DOI: 10.1002/rmv.2225
sha: 960d9b0f172f0ffc61e0523ff78384b006ad73b4
doc_id: 867431
cord_uid: a2sr8elt

Convalescent plasma therapy (CPT) has been investigated as a treatment for COVID‐19. This review evaluates CPT in COVID‐19 and other viral respiratory diseases, including severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS) and influenza. PubMed and Google scholar databases were used to collect eligible publications until 8 December 2020. Meta‐analysis used Mantel–Haenszel risk ratio (RR) with 95% confidence interval (CI) and pooled analysis for individual patient data with inverse variance weighted average. The study is registered at PROSPERO with the number of CRD4200270579. Forty‐four studies with 36,716 participants were included in the pooled analysis and 20 studies in the meta‐analysis. Meta‐analysis showed reduction of mortality (RR 0.57, 95% CI [0.43, 0.76], z = 3.86 [p < 0.001], I (2) = 44% [p = 0.03]) and higher number of discharged patients (RR 2.53, 95% CI [1.72, 3.72], z = 4.70 [p < 0.001], I (2) = 3% [p = 0.39]) in patients receiving CPT compared to standard care alone. A possible mechanism of action is prompt reduction in viral titre. Serious transfusion‐related adverse events were reported to be less than 1% of cases, suggesting the overall safety of CPT; nevertheless, the number of patients participating in the studies was still limited. It is also important to notice that in all the studies, the majority of patients were also given other medications, such as antivirals, antibiotics and corticosteroid; furthermore, randomized controlled studies involving more patients and in combination with other treatment modalities are urgently needed.

Severe acute respiratory syndrome-coronavirus-2 (SARS- infections emerged at the end of January 2020, leading World Health Organization (WHO) to declare COVID-19 as a Public Health Emergency of International Concern, and later updated the status into pandemic. Up to 2 October 2020, 216 countries were affected with 1,023,522 (4%) deaths and 25,634,071 (96%) recovered among 26 ,657,593 confirmed cases. 1 The disease, later known as COVID-19, is mainly characterized by myalgia, fever, cough, dyspnoea, sore throat, dizziness and confusion. Laboratory and radiological examinations often reveal decreased albumin, high C-reactive protein (CRP), lymphopenia and pneumonia. 2 These clinical symptoms are similar with the previous cases of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS) and influenza. 3 Further genetic findings confirmed that a significant proportion of genetic sequences in SARS-CoV (79%) and MERS-coronavirus (MERS-CoV) (50%) are identical with SARS-CoV-2. 4 Up until now, no specific and efficient pharmacological therapy has been validated. Chloroquine, a drug commonly used to treat malaria, is suggested to be effective against SARS-CoV-2 in vitro. 5 Hydroxychloroquine, one of the chloroquine derivatives, is suggested to be more potent than chloroquine, with less toxicity 6 ; however, recent systematic reviews based on 19 studies have shown antiviral treatments, including ribavirin, favipiravir, lopinavir/ritonavir, umifenovir, interferon and hydroxychloroquine, which exhibit no beneficial effects in both mild and severe COVID-19 patients when compared to control. 7 Remdesivir, a monophosphoramidate prodrug, has a broad antiviral activity against human coronaviruses, including SARS-CoV, MERS-CoV, CoV-OC43, CoV-229E and SARS-CoV-2 in vitro.

Remdesivir reduces viral titre, thus improving pulmonary lesions and respiratory function in SARS-CoV MA15-infected mice and SARS-CoV-2-infected rhesus macaques. 8 Two meta-analyses showed that remdesivir is associated with better overall clinical recovery 9,10 ; however, no evidence suggests any differences in terms of mortality between remdesivir versus standard care. 10, 11 Another therapeutic approach having been intensively investigated is immunotherapies. Immunotherapies, such as convalescent plasma therapy (CPT) (polyclonal antibody), monoclonal antibodies, hormone for T-cell maturation and ACE2 immunoadhesins, focus on promoting patients' immune system against viral infection. 12 In CPT, blood plasma from recovered individuals is expected to contain high titre of neutralizing antibody, thus transplanted into newly infected patients. 13, 14 CPT has been used in previous outbreaks of viral infections, such as Ebola virus, 15 Lassa fever, 16 Junin virus of Argentinian haemorrhagic fever, 17 Spanish flu influenza, 18 H1N1 influenza, 19 H5N1 avian influenza, 20 Encouraging results from CPT application in other severe acute respiratory infection cases suggest the potential of this therapy in COVID-19 patients. 13 This study aims to evaluate the potentials of CPT to COVID-19 patients by performing systematic review and meta-analysis on the published application of CPT in COVID-19, influenza, SARS and MERS patients. Since the data on CPT in COVID-19 patients are not abundant yet, the inclusion of studies in other viral respiratory diseases is important to obtain an objective overview of this treatment method, including patients' characteristics, infection states, adverse effects and outcomes.

This systematic review and meta-analysis were conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guidelines. 23 including original data, such as reviews, systematic reviews, comments or editorial letters; (c) not written in English; (d) using monoclonal antibody therapy or manufactured immunoglobulin; (e) using vaccination to enhance immune response; (f) using other intervention other than standard care as control; and (g) performed on animals.

For meta-analysis synthesis, case reports, case series or studies which were not reporting comparison standard care group were excluded.

analysis, the parameters considered as primary outcomes included status at 7 and 30 days after intervention and serious transfusionrelated adverse effects. Status after intervention is classified into four groups: discharged, hospitalized, deceased and alive. Outcomes are defined as additional data used to assess patients' improvement after intervention, including laboratory findings, time to negative viral titre and oxygenation.

In meta-analysis, primary outcomes included mortality and discharge rates, while secondary outcomes included clinical improvement and viral nucleic acid negative rates in the treated groups (CPT-receiving patients) versus control groups (standard care alone). Mortality is defined as a cumulative number of deaths after 30-day intervention. Discharge rate is defined as the number of patients discharged from the hospital after 7 or 28 days after intervention. Clinical improvement is defined as an increase by 6 or 8 points in WHO disease severity scale, 26 and improvement of oxygenation at 14 days after intervention. Viral nucleic acid negative rate is defined as the number of patients with undetectable viral load via polymerase chain reaction (PCR) assay during 1, 2, 3 or 7 days after intervention. The above-mentioned analysis was performed for all diseases severity, time-to-transfusion, and antibody titre; furthermore, we also did meta-analysis of possible confounding factors which might affect CPT outcomes, including diseases severity and convalescent plasma antibody titre. Disease severity was clas- Only RCTs, match-control observational studies or single-arm studies with subgroup analysis were included for meta-analysis. One study, Joyner et al. (2020) 49 was excluded from the meta-analysis as there was duplication of data with Joyner et al.. 48 Characteristics of the included studies are presented in Table S1 .

Baseline characteristics of patients receiving CPT are shown in Table 1 . The majority of patients receiving CPT in COVID-19 group were 40-70 years old. There were more male patients compared to female ones, which were especially observable in COVID-19 cases aspartate aminotransferase (AST) and total bilirubin levels were normal prior to and after CPT transfusion. Lactate dehydrogenase (LDH) and ferritin levels were elevated above normal range before and after transfusion; however, the levels were decreased within 7-14 days after transfusion (Table 3 ).

Meta-analysis was performed on studies comparing patients receiving CPT with patients treated with standard care (control). RCTs are presented on Table S2 and Figure S1 , while the risks of bias in non-RCTs are presented on Table S3 and 

The comparison of number of discharged CPT-treated patients to untreated patients was reported during 7 and 28 days after transfusion in five 27 (Table S4 ).

Subgroup analysis for diseases severity and antibody titre was not possible for these particular outcomes as very limited studies reported the subgroup analysis. (Table S4 ). Subgroup analysis for diseases severity and antibody titre was not possible for these outcomes since only few studies reported the subgroup analysis. Figure 6 ). No publication bias or small-study effect was found (Table S4 ). Subgroup analysis for disease severity and antibody titre was not possible for these outcomes as subgroup analysis was reported in very few of the studies.

I 2 = 57% [p = 0.02]) (

There were some known conditions affecting the effect of CPT Biologically, SARS-CoV-2 uses angiotensin converting enzyme 2 (ACE2), which is highly expressed in heart, lungs, kidney and gastrointestinal tract as an initial binding receptor for infection.

Interestingly, patients with hypertension and cardiovascular diseases demonstrated elevated ACE2 expression; therefore, they could have a risk to acquire more severe symptoms of COVID- 19. 81 In influenza cases, cardiovascular diseases, especially atherosclerosis, is associated with an increased risk of influenza infection since atherosclerosis plaque can function as carriers of influenza viruses for a long period of time. 82 Obesity had been known to be correlated with the COVID-19 and influenza infection as it reduced and delayed capacity to produce interferons, thereby allowing more viral RNA replication. 83 Obesity even impairs functions of the mucociliary cells, therewith reducing the clearance of the viruses. 84 Our results showed that diabetes is the second most common major comorbidity in COVID-19, but not in influenza. This might be related to the elevated circulating level of furin, a cellular protease involving in facilitating viral entry by cleaving S1 and S2 domains of SARS-CoV-2 spike protein in patients with diabetes mellitus. 85 Underlying respiratory disease is another major comorbidity aside from hypertension in influenza patients, but not in COVID-19 pa- remarkably higher than mortality rates in influenza cases. Thirty-day mortality rates were reported just in COVID-19 and influenza cases.

Mortality in COVID-19 cases was more than twofold higher compared to influenza cases. Our results are in line with previous reports where overall in-hospital mortality rates were higher in COVID-19 cases compared to influenza and SARS-CoV cases. [86] [87] [88] Clinical improvements were seen in COVID-19 patients receiving CPT. Improvement of oxygenation was seen within 7-day posttransfusion. Reduced lymphocyte counts were noticed before transfusion which was significant in severe/critical patients. 89 The levels of IL-6 and CRP increased significantly in patients on admission. IL-6 is a pro-inflammatory cytokine elevated during bacterial or viral infection. It is the primary trigger for cytokine storms. CRP is induced by IL-6 in the liver whose level increases dramatically during acute inflammatory responses. A cohort study involving 140 patients showed patients with IL-6 >32.1 pg/ml or CRP >41.8 mg/L were more likely to have severe complications. 90 Ferritin levels were also elevated during admission. Ferritin is a key mediator of immune dysregulation contributing to cytokine storm which indicated the admitted patients had severe inflammatory conditions. 91 CPT transfusion was associated with resolved inflammatory conditions in 1-2 weeks mean time (Table 3) . ALT, AST and total bilirubin levels were normal before and after CPT transfusion indicating that the majority of the patients did not experience kidney function impairment. 92 LDH level was elevated indicating that most of the patients were in severe to critical conditions. 93

The meta-analyses showed that the differences in mortality between COVID-19 patients who did and did not receive CPT were significant ( Figure 2 ). The same finding was also identified in influenza 

Meta-analysis of factors affecting convalescent plasma therapy outcomes as indicated with mortality rate and length of hospital stay. Only COVID-19 cases can be subgroup analysed for disease severity: severe versus critical. The outcome assessed here were comparison of (a1) mortality rate and (a2) length of hospital stays, while analysis of mortality for comparison of antibody titre was carried out for COVID-19 and influenza cases (b) antivirals, antibiotics, corticosteroid and immunomodulatory or immunosuppressive agents; therefore, it remains plausible to assess the possibilities to use CPT in combination with other medications for patients with viral respiratory diseases, such as COVID-19.

Based on the results from meta-analyses, it is safe to conclude that CPT is a potential therapy to accelerate the decrease of viral titres, thus expecting to increase the rates of hospital discharge and decrease the rates of mortality. Since CPT is used as a part of multimodality treatment for COVID-19 patients, development of other drugs included in the treatment will also affect the post-CPT outcomes.

The authors would like to thank Alya Mardhotillah Azizah and Ika

Adhani Sholihah from Universitas Pendidikan Indonesia for giving some valuable inputs at the initiation of this study.

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

The authors declare no conflicts of interest.

The data supporting the findings of this study are available in the supplementary material of this article.

Not required. 

COVID-19 Coronavirus Pandemic

Clinical, laboratory, and imaging features of COVID-19: A systematic review and meta-analysis

Convalescent plasma in COVID-19: possible mechanisms of action

Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCov) in vitro

In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-Cov-2 and other acute viral infections: a systematic review and meta-analysis

Remdesivir and its antiviral activity against COVID-19: A systematic review

Effect of remdesivir on patients with COVID-19: a network meta-analysis of randomized control trials

Efficacy of various treatments modalities for nCOV-2019: a systematic review and meta-analysis

Interventions for treatment of COVID-19: A living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)

Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection

Convalescent plasma transfusion for the treatment of COVID-19: systematic review

Antibody-based immunotherapeutics and use of convalescent plasma to counter COVID-19: advances and prospects

A meta-analysis of clinical studies conducted during the West Africa Ebola virus disease outbreak confirms the need for randomized control groups

The use of Lassa fever convalescent plasma in Nigeria

Treatment of argentine hemorrhagic fever with convalescent's plasma. 4433 cases

Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?

Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection

Treatment with convalescent plasma for influenza A (H5N1) infection

Use of convalescent plasma therapy in SARS patients in Hong Kong

Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration

The Cochrane collaboration's tool for assessing risk of bias in randomized trials

The Risk of bias in nonrandomized studies of interventions (ROBINS-I) assessment tool

World Health Organization. WHO R&D blueprint novel coronavirus: COVID-19 therapeutic trial synopsis. R&D Bluepr

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research

A randomized study of antiinfluenza immune plasma for the treatment of severe influenza A

Immune plasma for the treatment of severe influenza: an open-label, multicenter, phase 2 randomised study

Convalescent plasma for COVID-19: A randomized clinical trial. medRxiv

Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and lifethreatening COVID-19

The therapeutic effectiveness of convalescent plasma therapy on treating COVID-19 patients residing in respiratory care units in Baghdad

Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicenter randomized controlled trial

Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients

Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: results of a multicenter clinical study

Use of convalescent plasma in hospitalized patients with COVID-19: case series

Convalescent plasma treatment of severe COVID-19: A matched control study

Convalescent plasma for patients with severe COVID-19: a matched cohort study. medRxiv

Improved clinical symptoms and mortality among patient with severe or critical COVID-19 after convalescent plasma transfusion

Effect of convalescent plasma therapy on viral shedding and survival in patients with coronavirus disease 2019

Convalescent plasma for the treatment of patients with severe coronavirus disease 2019: A preliminary report

Effectiveness of convalescent plasma for treatment of COVID-19 patients

Clinical and laboratory evaluation of patients with SARS-Cov-2 pneumonia treated with high-titre convalescent plasma: a prospective study

Life-saving effect of convalescent plasma treatment in COVID-19 disease: clinical trial from eastern Anatolia

Hospitalized COVID-19 patients treated with Convalescent Plasma in a mid-size city in the Midwest. medRixv

Treatment of six COVID-19 patients with convalescent plasma

Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience

Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients

Initial experience in Mexico with convalescent plasma in COVID-19 patients with severe respiratory failure, a retrospective case series

Infusion of convalescent plasma is associated with clinical improvement in critically ill patients with COVID-19: a pilot study

Mortality reduction in 46 severe COVID-19 patients treated with hyperimmune plasma. Haematologica

Treatment of coronavirus disease 2019 (COVID-19) patients with convalescent plasma

Treatment of 5 critically ill patients with COVID-19 with convalescent plasma

Factors associated with good patient outcomes following convalescent plasma in COVID-19: A prospective phase II clinical trial

Successful treatment of avian-origin influenza A (H7N9) infection using convalescent plasma

Treatment of severe acute respiratory syndrome with convalescent plasma

Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital

Severe refractory COVID-19 patients responding to convalescent plasma, A case series

Use of convalescent plasma therapy in two COVID-19 patients with Acute respiratory disease syndrome in Korea

Convalescent plasma for persisting COVID-19 following therapeutic lymphocyte depletion: a report of rapid recovery

Successful treatment of a centenarian with coronavirus disease 2019 (COVID-19) using convalescent plasma

Convalescent plasma to treat COVID-19: Chinese strategy and experiences. medRxiv

Clinical characteristics and convalescent plasma therapy in severe and critically ill COVID-19 patients

Treatment with convalescent plasma for COVID-19 patients in Wuhan

Treatment with convalescent plasma for critically ill patients with SARS-Cov-2 infection

Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomized, placebocontrolled trial

INSIGHT FLU005: An antiinfluenza virus hyperimmune intravenous immunoglobulin pilot study

Hyperimmune IV immunoglobulin treatment: A multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A (H1N1) infection

Intravenous immunoglobulin (IVIG) significantly reduces respiratory morbidity in COVID-19 pneumonia: A prospective randomized trial

Short-term moderate-dose corticosteroid plus immunoglobulin effectively reverses COVID-19 patients who have failed low-dose therapy. Res Square

High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. Open Forum Infect Dis

Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19

Clinical efficacy of intravenous immunoglobulin therapy in critical patients with COVID-19: A multicenter retrospective cohort study

Efficacy of convalescent plasma therapy compared to fresh frozen plasma in severely ill COVID-19 patients: a pilot randomized controlled trial

Possible transfusion-related acute lung injury following convalescent plasma transfusion in a patient with Middle East respiratory syndrome

Reclassifying acute respiratory distress syndrome

Presenting characteristics, comorbidities and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area

Association of cardiovascular disease and 10 other preexisting comorbidities with COVID-19 mortality: A systematic review and meta-analysis

Description and comparison of demographic characteristics and comorbidities in SARI from COVID-19, SARI from influenza, and the Brazilian general population

COVID-19, hypertension and cardiovascular diseases: should we change the therapy?

Influenza and cardiovascular disease: does swine-origin, 2009 H1N1 flu virus represent a risk factor, an acute trigger, or both

Influenza and obesity: its odd relationship and the lessons for COVDI-19 pandemic

Obesity and COVID-19: molecular mechanisms linking both pandemics

Perspective: COVID-19 pandemic, coronaviruses, and diabetes mellitus

Clinical outcomes and characteristics of patients hospitalized for influenza or COVID-19 in Germany

Comparing SARS-Cov-2 with SARS-Cov and influenza pandemics

Potential association between COVID-19 mortality and health-care resource availability

Lymphocyte subset counts in COVID-19 patients: a meta-analysis

Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19

Ferritin levels and COVID-19

Variation of traditional biomarkers of liver injury after an ultramarathon at altitude

Current views on the potentials of convalescent plasma therapy (CPT) as Coronavirus disease 2019 (COVID-19) treatment: A systematic review and metaanalysis based on recent studies and previous respiratory pandemics